EU ADR App To Underpin Region’s Regulatory Approach To Social Media
This article was originally published in The Pink Sheet Daily
Executive Summary
EU regulators are set to launch an adverse drug reaction reporting app in March and will follow this up with a social media monitoring drive to improve pharmacovigilance.
You may also be interested in...
Europe Renews Innovative Medicines Initiative, With Funding Boost
With a new budget of €3.4 billion over the next seven years, Europe’s public-private partnership in health aims to tackle difficult-to-treat neurodegenerative diseases and new antibiotics.
MedWatch’s Patient-friendly Reporting Form Might Need An Overhaul
Promotion of the consumer MedWatch form needs to be improved if more physicians and consumers are to use it, FDA’s Risk Communications Advisory Committee says.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.